ORION -B- (OFK BE) stock market data APIs
€68.2369
0(0%)
as of October 14, 2025
Try our APIs with
free plan!
ORION -B- Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for OFK.BE.
Prev. Close
68.2369
Open
68.2369
High
68.2369
Low
68.2369
52 wk Range
41.2542-71.65
Market Cap
4 882 M
EPS
1.32
Dividends (Yield)
0.0443
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ORION -B- data using free add-ons & libraries
Get ORION -B- Fundamental Data
ORION -B- Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2018-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ORION -B- News
New
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
Orion Oyj ORION CORPORATION PRESS RELEASE 14 OCTOBER 2025 at 11.15 EEST Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 Orion will publish Int...
Could Orion Oyj’s Latest Insomnia Trial Result Hint at Challenges in R&D Strategy (HLSE:ORNBV)?
Orion Corporation announced that its candidate ODM-105 (tasipimidine) did not meet the primary endpoint in the Phase 2 UNITAS study for insomnia, with results showing no significant improvement over p...
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
Maxion Therapeutics Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled rece...
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
Orion Oyj ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 fo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
